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    INTRODUCTION 
 
 “The difficulty lies, not in the new ideas, but in escaping the old ones, 
which ramify, for those brought up as most of us have been, into every corner of 
our minds.”    Keynes, John Maynard 
In most chronic illness, defects arise in thyroid hormone metabolism, 
resulting in the sick euthyroid syndrome. This is characterized by a normal 
total T4, normal/high free T4, low total T3, low free T3 and an elevated rT3. 
These changes reflect a reduction in D1 activity, an increase in D3 and changes 
in the plasma concentration of thyroid-binding proteins and free fatty acids 
(which displace thyroid hormones from binding proteins) There are also non-
thyroidal influences on the hypothalamic-pituitary-thyroid axis, e.g. cortisol 
inhibiting TSH secretion(1). It has been suggested that this syndrome may confer 
a survival advantage, which adapts an organism to chronic illness by reducing 
the basal metabolic rate within cells and thereby reducing caloric requirements. 
  
 In the different types of liver disease, similar processes may occur to 
those seen in the sick euthyroid syndrome, but in addition a number of changes 
specific to the type or stage of liver disease is also found. Many studies have 
been carried out in liver disease patients assessing their thyroid status; mostly in 
European countries and Japan. Most of these studies are limited by the number 
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of patients in which these studies have been conducted. This study tries to find 
out the relationship between thyroid function and liver disease in the context of 
a tertiary care hospital in India. This study focuses on patients with 
complications of liver disease who are sicker than the patients in other studies. 
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    Aims and objectives 
 
1.   To determine the spectrum of thyroid abnormalities in both 
chronic and acute liver disease patients admitted in   medical wards in 
Government General Hospital. 
 
2.   To compare the thyroid hormone levels in the liver diseases- both 
acute and chronic patients to that of healthy controls. 
 
3. To assess the correlation between  thyroid function and  the level 
of liver dysfunction. 
 
4. To  assess the utility of thyroid function tests as a biomarker to 
differentiate acute from chronic liver disease. 
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Review of Literature 
 
 
 In normal subjects, the thyroid gland secretes 110 nmol of thyroxine and 
10 nmol of triiodothyronine each day(2). Tri-iodothyronine has a ten times 
greater affinity and ten times greater efficacy than thyroxine for the nuclear 
receptor, thus even though thyroxine is quantitatively secreted at much higher 
levels, it should be regarded as a pro-hormone that requires deiodination and 
conversion to T3 to become biologically active(3). There are three groups of 
enzymes that regulate thyroid hormone metabolism, forming part of the 
iodothyronine seleno-deiodinase enzyme system (type 1 = D1, type 2 = D2 and 
type 3 = D3). They are responsible for the activation of T4 to T3, inactivation of 
T4 to rT3 and the conversion of rT3 and T3 to T2. 
The conversion of T4 to T3 in extra thyroidal tissue occurs through a rapidly 
equilibrating pool via the D1 enzyme system and a slowly equilibrating pool 
Via the D2 system. The type 1 deiodinase is mainly found in the liver and 
kidney(4), and accounts for approximately 30–40% of extrathyroidal production 
of T3 (12 nmol). The type 2 deiodinase is found in the pituitary, the CNS, and 
skeletal muscle and contributes 60–70% of the extrathyroidal production of T3 
(30 nmol)(5). Although this enzyme system performs similar actions to the D1 
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group of enzymes, its kinetics, regulation and susceptibility to 
propylthiouracil(6) are different. Although both the D1 and D2 system can also 
inactivate T4 and T3, the major inactivator is the type 3 deiodinase system, 
which primarily exhibits inner-ring deiodination (unlike the other systems). It is 
found in the liver, skin and CNS, where it catalyses the conversion of T4 to rT3 
and T3 to T2, both inactive metabolites; it also converts rT3 to rT2(7). This 
enzyme system is also expressed in placenta, where it protects the foetus from 
maternal thyroid hormones(8). 
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Structures of principal iodothyronines and their interactions(1)  
 
 
 
In addition to the central role in deiodination to activate and deactivate 
thyroid hormones, the liver performs specific functions relating to thyroid 
hormone transport and metabolism. The liver extracts 5–10% of plasma T4 
during a single passage, as shown by studies using w131IxT4. This value is 
much higher than can be accounted for by the amount of free T4 delivered to 
the liver, indicating that a substantial amount of proteinbound T4 is available 
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for uptake[9]. An active stereospecific transport mechanism has been identified 
for transporting T4 and T3 across the hepatocytes membrane. The intracellular 
concentrations of the free hormone are higher than the plasma levels, and the 
process is energy-dependent[10]. 
The liver synthesizes a number of plasma proteins that bind the lipophilic 
thyroid hormones and thereby provide a large, rapidly exchangeable pool of 
circulating hormone. The thyroid hormones are 99% bound to thyroxine-
binding globulin, thyroxine-binding prealbumin and albumin in plasma. The 
free hormone component within plasma is in equilibrium with the protein-bound 
hormone, and it is this free fraction which accounts for the hormone’s biological 
activities. The plasma concentrations of free T4 and T3 are at a steady 
concentration, so that the tissues are exposed to the same concentrations of the 
free hormone. However, the free hormone concentrations in different tissues 
vary according to the transport and deiodinase activity within specific tissues. 
Thus tissue thyroid status depends not only on thyroxine secretion but also on 
normal thyroid hormone metabolism, delivery of T3 to nuclear receptors and on 
receptor distribution and function. Normal thyroid function, which is essential 
for normal growth, development and the regulation of energy metabolism 
within cells, is dependent on a normally functioning thyroid and liver axis. 
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Thyroid abnormalities in specific liver diseases Cirrhosis liver 
 
The most consistent thyroid hormone profile in patients with cirrhosis are 
a low total and free T3[11]  and an elevated rT3[12], similar changes to those in 
the sick euthyroid syndrome, probably reflecting a reduced deiodinase type 1 
activity, resulting in reduced conversion of T4 to T3. This results in an increase 
in conversion of T4 to rT3 by the deiodanase type 3 system, and an increase in 
the rT3 to T3 ratio. The plasma T3:rT3 ratio has a negative correlation with the 
severity of cirrhosis when assessed in non-alcoholic cirrhotics[13]. Since T3 and 
rT3 bind to the same plasma proteins, the 
T3/rT3 ratio provides a parameter of liver function that is largely independent of 
protein binding. Both the T3/rT3 ratio and free T3 levels in plasma thus 
provide a correlate of liver function in cirrhosis, and are of prognostic value, 
albeit seldom used[14]. The low total and free T3 levels may be regarded as an 
adaptive hypothyroid state that serves to reduce the basal metabolic rate within 
hepatocytes and preserve liver function and total body protein stores. There are 
reports of improvement in liver function with the onset of hypothyroidism in 
patients with cirrhosis. Controlled induction of hypothyroidism might therefore 
be beneficial in cirrhotic patients[15], but further studies are required to test this 
hypothesis. 
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  Acute hepatitis and acute liver failure 
  
In acute hepatitis of mild or moderate severity, patients have elevated serum 
levels of total T4, due to increased thyroid-binding globulin[16], which is 
synthesized as an acute-phase reactant, but normal levels of free T4. In more 
severe cases with impending liver failure, the data is variable, and low total T4 
levels may reflect reduced hepatocellular synthesis of thyroid-binding globulin. 
Serum T3 levels are extremely variable, but the free T3:T4 ratio correlates 
negatively with the severity of the liver disease and has prognostic value[16]. 
Again this probably reflects diminished type 1 deiodinase activity, resulting in a 
reduced conversion of T4 to T3; in general, however, these patients are 
clinically euthyroid. Some series have described patients with acute hepatic 
failure (especially viral hepatitis) as having goitres that resolved with 
improvement in liver function[17]. 
 
    Specific forms of chronic liver disease 
  
 In patients with chronic hepatitis associated with primary biliary cirrhosis 
(PBC) or chronic autoimmune hepatitis, there is an increased prevalence of 
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autoimmune thyroid disease[18, 19]. Thus abnormalities may arise from thyroid 
gland dysfunction or as a consequence of the liver disease. Autoimmune 
hypothyroidism is a prominent feature in PBC, occurring in 10–25% of 
patients[20]. There is often an increase in total T4 in PBC, due to an increase in 
thyroid-binding globulin levels and this may mask hypothyroidism, 
emphasizing the need to perform a free T4 and TSH assay. Anti-thyroid 
microsomal antibodies are common in PBC (34%), as are antithyroglobulin 
antibodies (20%). Thyroid dysfunction may precede or follow the diagnosis of 
PBC. In autoimmune hepatitis, both Grave’s disease (6%) and autoimmune 
hypothyroidism (12%) are relatively common[19]. Primary sclerosing cholangitis 
is associated with an increased incidence of Hashimoto’s thyroiditis, Graves’s 
disease and Riedel’s thyroiditis[21]. 
 
 In patients with chronic hepatitis who do not have co-existing 
autoimmune liver and thyroid disease, total T4, total T3, thyroxine-binding 
globulin levels are often increased, but TSH and free T4 levels are usually 
normal, and patients are clinically euthyroid[22]. 
 
 Patients with decompensated liver disease complicated by hepatic 
encephalopathy subsequent to non-alcoholic cirrhosis were also found to have 
exceedingly low serum FT3 and T4 levels. Depressed serum FT3 and T4 levels, 
together with a prolonged prothrombin-time, appear to be characteristic of a 
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subgroup of decompensated non alcoholic cirrhotic patients prone to develop 
hepatic encephalopathy. 
 
Thyroid abnormalities associated with treatment of liver disease 
 
Currently the treatment of viral hepatitis with alpha interferon has added 
another dimension to the abnormalities of thyroid function seen in chronic liver 
diseases. In different studies assessing patients treated with alpha interferon for 
hepatitis C, 2.5–10% developed thyroid dysfunction, with both thyrotoxicosis 
(due to acute thyroiditis) and hypothyroidism being observed. Although the 
reason is not altogether clear, the induction of an autoimmune reaction has been 
postulated, resulting in the development of anti-thyroid and antithyrotrophin 
receptor antibodies[23]. However, a distinct effect on intrathyroidal 
organification of iodine has also been suggested[24]. The risk factors for 
developing thyroid dysfunction with alpha interferon (which may persist after 
discontinuation of the drug) are female sex, underlying malignancy, high doses 
of long duration, combination immunotherapy (especially Il-2), and the 
presence of antithyroid peroxidase antibodies prior to commencing 
treatment[25,26,27]. It should be noted that interferon therapy causes weakness and 
muscle aching, and in this setting the myopathy of hypothyroidism may be 
missed. It is therefore recommended that thyroid function tests (including 
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thyroid antibodies) are performed prior to therapy, and subsequently monitored 
at 3–6 month intervals during interferon therapy[28]. 
 
 Overall, the majority of patients with liver disease are clinically 
euthyroid, and this can be confirmed with a normal high sensitivity TSH test 
and a normal free T4. The latter test is routinely performed and obviates the 
need to take into account the variation in thyroid-binding globulin levels seen in 
patients with liver disease. 
 
 Hypothyroidism as a treatment option in liver disease 
 
 Hyperdynamic circulation observed in portal hypertension is 
characterized by pronounced vasodilatation, increased systemic and regional 
blood flows, and augmented cardiac index. Drugs used for the treatment of 
portal hypertension, such as β-adrenergic blocking agents, have also proved 
useful in controlling the cardiovascular manifestations of thyrotoxicosis. 
Moreover, propylthiouracil, a commonly used drug for the treatment of 
hyperthyroidism, has been used for the management of patients with alcoholic 
liver disease with favourable response.  In a rat model of portal vein ligation, 
hypothyroidism caused amelioration of the hyperdynamic circulation followed 
by reduction of the portal pressure[29]. Therefore, alleviation of the 
20 
 
hypermetabolic state by thyroid hormone manipulation has been proposed as a 
treatment option for the hyperdynamic circulation observed in the portal 
hypertensive state 
There is an interesting study demonstrating that hypothyroidism by 
chronic methimazole administration can alleviate the degree of liver injury and 
hepatic encephalopathy in bile-duct ligated cirrhotic rats[30]. However, the 
underlying mechanisms responsible for this phenomenon remain incompletely 
understood, but immunomodulation and minimization of oxidative liver injury 
are possible mechanisms. Further studies on the pathogenesis are needed to 
justify whether hypothyroidism can be used as a treatment option during 
conditions of liver injury and hepatic encephalopathy. 
 
    Liver abnormalities in thyroid disease  
Hypothyroidism 
 
 Hypothyroidism may have features that mimic liver disease (pseudo-liver 
disease): examples include myalgias, fatigue and muscle cramps in the presence 
of an elevated aspartate aminotransferase from a myopathy[31], coma in 
myxoedema coma[32], and myxoedema ascites[33]. Myxoedema ascites, generally 
a high protein content ascites suggestive of an exudate, has been varyingly 
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interpreted as an intrinsic liver defect or a phenomenon mimicking liver disease. 
It had been proposed that the ascites was a consequence of chronic right-sided 
heart failure, resulting in central scarring of the liver[34]. The liver biopsy 
findings of central congestive fibrosis in a number of patients would support 
this. However, another study reported normal right heart pressures, and 
proposed that severe hypothyroidism caused enhanced permeability of vascular 
endothelium, resulting in ascites and serous effusions throughout the body. 
Following initiation of thyroid replacement therapy, myxoedema ascites 
resolves over a few months. There is also evidence that hypothyroidism may 
directly affect the liver structure or function. Hypothyroidism has been 
associated in a few case reports with cholestatic jaundice attributed to reduced 
bilirubin and bile excretion. In experimental hypothyroidism, the activity of 
bilirubin UDP-glucuronyltransferase is decreased, resulting in a reduction in 
bilirubin excretion[34]. The reduction in bile flow may be in part due to an 
increase in membrane cholesterol-phospholipid ratio and diminished membrane 
fluidity[34], which may affect a number of canalicular membrane transporters 
and enzymes, including the Naq, Kq-ATPase. The triad of reduced bilirubin 
excretion, hypercholesterolemia and hypotonia of the gall bladder seen in 
hypothyroidism increases the incidence of gallstones[35]. Recent studies have 
shown that the hepatic abnormalities associated with hypothyroidism can be 
reversible over a matter of weeks with thyroxine replacement, with no residual 
liver damage[36,37]. In rats, hypothyroidism may protect against acetaminophen 
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toxicity and diminish thioacetamide toxicity, but there is no evidence for this in 
man[38,39]. 
 
 
  Hyperthyroidism 
 
 
 
The clinical features of hyperthyroidism are diverse, involving nearly 
every system in the body. Liver injury caused by thyrotoxicosis is relatively 
common, and can be conveniently divided into hepatitic or cholestatic types. 
An increase in the aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) was reported in 27% and 37% of patients 
respectively[40], although the majority of these patients showed no other clinical 
or biochemical features of liver impairment. The mechanism of injury appears 
to be relative hypoxia in the perivenular regions, due to an increase in hepatic 
oxygen demand without an appropriate increase in hepatic blood flow. In mild 
cases, liver histology shows non specific changes, which on light microscopy 
consist of a mild lobular inflammatory infiltrate consisting of polymorphic 
neutrophils, eosinophils and lymphocytes, associated with nuclear changes and 
Kupffer cell hyperplasia. A small proportion of patients have a progressive liver 
injury, which histologically consists of centrizonal necrosis and perivenular 
fibrosis, affecting the areas in which hypoxia may be most prevalent. The 
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clinical presentation of this type of injury is usually that of a self-limiting 
hepatitis; however, there are a few case reports of thyrotoxic patients presenting 
with fulminant hepatic failure[41]. The precipitation of the clinical presentation is 
generally attributable to the onset of cardiac failure, often precipitated by 
arrhythmias[41]. 
 
Cholestatic injury 
 
An elevated serum alkaline phosphatase is seen in 64% of patients with 
thyrotoxicosis[42]. However this is not necessarily liver-specific, as it can 
originate from bone and/or liver. It is therefore important to look at elevations in 
c-glutamyl transpeptidase (17%) and bilirubin (5%) as an indicator of 
cholestasis[42]. In patients with cholestatic injury, the histological features are 
similar to the nonspecific changes seen in hepatitic injury. However, in addition 
there appears to be centri-lobular intrahepatocytic cholestasis[43].  Jaundice is 
uncommon but when it occurs, complications of thyrotoxicosis (cardiac 
failure/sepsis) or intrinsic liver disease need to be excluded. It is difficult to 
establish which features seen in thyrotoxic liver injury are from tissue thyroid 
status alone, and which are in combination with complications such as cardiac 
failure, malnutrition and sepsis. It is probably impractical to try and separate the 
causes out, as awareness of the presentation, complications and treatment are of 
greater importance. A spectrum of pathological changes from focal necrosis 
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with fatty change to cirrhosis has been reported in untreated hyperthyroidism[43]. 
Modern therapies have made chronic liver disease a very rare complication of 
hyperthyroidism[44]. In the vast majority of cases, the hepatic abnormalities 
associated with hyperthyroidism are reversible, following the early recognition 
and treatment of the disorder[44]. 
 
Hepatic Dysfunction Associated With Treatment of Hyperthyroidism 
 
Increased serum levels of aspartate aminotransferase and alanine 
aminotransferase occur in about 30% of patients treated with 
propylthiouracil[45]. The rise in AST appears to be dose-related, so that AST and 
ALT levels are highest during the first few weeks of treatment, falling rapidly 
with a dose reduction[46]. In the majority of patients, serum aminotransferases 
return to normal, with clinical improvement following withdrawal of treatment. 
Rarely, a persistent hepatitis occurs with clinical, biochemical (elevated 
bilirubin, AST and ALT) and histological features of hepatocellular necrosis[47]. 
This is an idiosyncratic reaction that can develop at any time, but usually occurs 
within the first 2 to 3 months of treatment in about 1% of patients, usually 
women aged -30 years. It is considered to be an allergic host response, which 
generally resolves over a protracted period of time[48]. A small proportion of 
patients develop fulminant hepatic failure, with the presence of severe acidosis 
or a combination of grade III/IV encephalopathy, renal failure and 
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coagulopathy. Abnormalities of liver function are much less common with 
carbimazole and methimazole. These agents induce cholestasis, as an 
idiosyncratic reaction to the drug[49]. An elevation of the bilirubin, alkaline 
phosphatase, and c-glutamyl transpeptidase levels are the predominant 
abnormalities. Such liver dysfunction usually presents within 2–3 weeks of 
initiation of treatment, and can persist for several months despite 
discontinuation of the offending drug[50]. The predominant feature on liver 
biopsy is intrahepatic cholestasis. Predicting the occurrence of hepatic injury in 
individual patients is difficult, and it is therefore recommended that liver 
function tests be performed in all patients within 3 months of commencing 
therapy. 
 
 
Other thyroid and liver interactions 
 
The liver is the major site for cholesterol and triglyceride metabolism, 
and the thyroid hormones play an integral part in hepatic lipid homeostasis. 
Thyroid hormones increase the expression of LDL receptors on the 
hepatocytes[51], and increase the activity of lipid-lowering liver enzymes, 
resulting in a reduction in low-density lipoprotein levels[52]. Thyroid hormones 
also increase the expression of apolipoprotein A1, a major component of high-
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density lipoprotein[53]. The above effects of the thyroid hormones could be 
beneficial in reducing the onset of atherosclerosis if they were elicited without 
the deleterious effects, particularly cardiac effects such as atrial 
arrhythmias[54,55]. A series of 3,5-diodo-3-aryl-substituted thyronines 
have been developed, which show a potent cholesterol-reducing effect in 
hypercholesterolaemic rats, without producing tachycardia. The tissue 
selectivity of these agents was attributed to selective uptake by the liver rather 
than TR subtype selectivity[56]. Subsequently, a series of novel thyronine type 
derivatives (dimethyl-isopropylbenzylphenoxy- acetic acid) (GC-1) have 
reduced serum cholesterol in rats, without tachycardia, by selective activation of 
the TRb isoform. 
 
  Diseases Affecting both Thyroid and Liver 
 
 Diseases causing diffuse infiltration like malignancies, amyloidosis and 
hemochromatosis can cause both thyroid and liver dysfunction. Of the 
infiltrating malignancies, non-Hodgkin’s lymphoma is the commonest cause, 
and the presentation is usually dominated by goitre (with or without 
lymphadenopathy), jaundice and a paraneoplastic illness[57]. Occasionally, other 
forms of hepatic impairment (e.g. coagulopathy) and hypothyroidism can occur 
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as part of the presentation[58]. Secondary amyloidosis due to systemic 
inflammatory diseases (e.g. Crohn’s, tuberculosis, familial Mediterranean 
fever) is the commonest cause of amyloid deposition into the liver and thyroid 
gland[59], characterized by the deposition of the serum amyloid A (AA) 
protein[60]. The synthetic function of each organ is usually well maintained, thus 
amyloid organ function is better followed by serial measurement of serum 
amyloid A protein and amyloid P scintigraphy[61]. Transfusion-related iron 
deposition (secondary hemochromatosis) can rarely cause multiple endocrine 
abnormalities (including hypothyroidism) and cirrhosis from iron deposition 
into the respective organ. The toxicity of the iron deposition into the thyroid 
(and thus degree of hypothyroidism) is potentiated by hypoxia and anemia, 
making these patients difficult to treat[62].
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 Drugs Affecting both Thyroid and Liver Diseases 
 
Amiodarone is the most notable drug that effects both the liver (fibrosis) 
and the thyroid gland (hypo/ hyperthyroidism), and its effects may remain even 
following drug withdrawal[63]. The antimalarial drug mefloquine can cause a 
self-limiting hepatitis and thyrotoxicosis from acute thyroiditis, but the 
symptoms appear to resolve when the drug is withdrawn[64]. Another major drug 
class affecting both organs is the anti-epileptics, of which carbamazepine 
can cause hepatic impairment and subclinical hypothyroidism from abnormal 
thyroid hormone metabolism[65]. Finally, the treatment of malignant disease 
using radical radiotherapy regimes, including those containing 131I MIBG 
and modern chemotherapy schedules have been associated with a greater degree 
of toxicity affecting both organs[66]. Studies on  the use of tri-iodothyronine as a 
hepatic growth factor has shown it to be a primary mitogen for the liver in 
animal models (i.e. it induces hepatocyte proliferation and increases liver mass 
when administered at high doses in the absence of hepatic injury)[67]. The ability 
to increase liver mass in the absence of liver damage, and to enhance 
proliferation during compensatory hyperplasia after liver damage, could be 
therapeutically valuable if applicable to man. More generally, the ability to 
manipulate liver cell proliferation in vivo may be helpful in designing cell 
transplantation and gene therapy approaches to liver diseases[68]. 
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  Prognostic markers in liver disease 
 
 Identifying patients with poor prognosis is important in planning 
treatment as well as in explaining the situation to the relatives of the patient. 
Prognostication of these patients is usually done by clinical examination and 
history. The introduction of liver cell transplantation as a very viable treatment 
modality has increased the importance of accurate prognostication in liver 
diseases. This has led to a search for newer biomarkers to better identify the 
prognosis. Various scoring systems like Child-Pugh, MELD and others have 
been devised to effectively identify patients with poor prognosis and those who 
will benefit from liver transplantation. The various prognostic indictors used in 
liver disease are briefly described below. 
 
    Child –Pugh score 
  
 Dr C.G. Child and Dr J.G. Turcotte of the University of Michigan first 
proposed the scoring system in 1964 . It was modified by Pugh in 1972[69]  . He 
replaced Child's criterion of nutritional status with the prothrombin time or INR, 
and thus eliminated the most subjective part of the score. Although it was 
originally used to predict mortality during surgery, it is now used to determine 
the prognosis, as well as the required strength of treatment and the necessity 
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of liver transplantation. The score employs five clinical measures of liver 
disease . Each measure is scored 1-3, with 3 indicating most severe 
derangement.
[70]
 In primary sclerosing cholangitis (PSC) and primary biliary 
cirrhosis (PBC), the bilirubin references are changed to reflect the fact that these 
diseases feature high conjugated bilirubin levels. The upper limit for 1 point is 
68 µmol/l (4 mg/dl) and the upper limit for 2 points is 170 µmol/l (10 mg/dl).  
 
 
Measure 1 point 2 points 3 points units 
Bilirubin (total) <34 (<2) 34-50 (2-3) >50 (>3) 
µmol/l 
(mg/dl) 
Serum albumin >35 28-35 <28 g/l 
INR <1.7 1.71-2.20 > 2.20 no unit 
Ascites None Mild Severe no unit 
Hepatic 
encephalopathy None 
Grade I-II (or 
suppressed with 
medication) 
Grade III-IV (or 
refractory) no unit 
 
Figure 1 child Pugh score 
 
 Chronic liver disease is classified into Child-Pugh class A to C, 
employing the added score from above. 
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Points Class One year survival Two year survival 
5-6 A 100% 85% 
7-9 B 81% 57% 
10-15 C 45% 35% 
     
   
 
    MELD SCORE 
  
 The Model for End-Stage Liver Disease, or MELD, is a scoring system 
for assessing the severity of chronic liver disease. It was initially developed to 
predict death within three months of surgery in patients that had undergone 
a transjugular intrahepatic portosystemic shunt (TIPS) procedure[71]. It uses the 
patient's values for serum bilirubin, serum creatinine, and the international 
normalized ratio for prothrombin time (INR) to predict survival. This score is 
also used by the United Network for Organ Sharing (UNOS) 
and Eurotransplant for prioritizing allocation of liver transplants. It is calculated 
according to the following formula[72]: 
MELD = 3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.57[Ln 
serum creatinine (mg/dL)] + 6.43 
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Caveats with the score include:  
 The maximum score given for MELD is 40. All values higher than 40 are 
given a score of 40 
 If the patient has been dialyzed twice within the last 7 days, then the 
value for serum creatinine used should be 4.0 
 Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8, a 
value of 1.0 is used). 
 
In interpreting the MELD Score in hospitalized patients, the 3 month mortality 
is: 
 40 or more — 100% mortality 
 30–39 — 83% mortality 
 20–29 — 76% mortality 
 10–19 — 27% mortality 
 <10 — 4% mortality 
 The equation seeks to calculate a patient’s likelihood of dying within 
three months from their liver disease. This scoring system is preferred by many 
centers for selecting patients for liver transplantation.   
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    Other models 
 
Other models for assessing the prognosis in liver disease include the following. 
 The original PBC model[73] 
 In this model, survival probability of a patient with primary biliary 
cirrhosis without treatment is estimated based on the following variables. The 
variables employed are age, serum bilirubin, serum albumin, prothrombin 
time, presence of peripheral edema and usage of diuretics. 
 
Updated PBC model for prediction of short‐term survival[74] 
  
In this model, short-term survival probability of a patient with primary 
biliary cirrhosis is estimated based on repeated observation. The same variables 
used in the original PBC model are used in this model also. 
 
   New PSC Model[75]
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 In this model, survival probability of a patient with primary sclerosing 
cholangitis is estimated based on the following variables. The variables are age, 
serum bilirubin, serum albumin and AST.  
 
 
 
 
The Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease  Index 
(ANI)[76] 
   
 The ANI is a novel scoring system that is highly accurate in 
distinguishing alcoholic liver disease (ALD) from nonalcoholic fatty liver 
disease (NAFLD). The ANI may be a useful tool for the frequent clinical 
scenarios in which it is useful to ascertain an alcohol basis for steatohepatitic 
liver injury. Short short-term abstinence does not significantly affect the 
performance characteristics of the ANI therefore the ANI is unlikely to be 
useful in detecting surreptious alcohol consumption in patients with known 
ALD. Other liver diseases should first be excluded before utilizing the ANI. The 
ANI is most accurate when the MELD Score is below 20. The variables used 
are AST, ALT, MCV, weight, height and gender. 
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   Prothrombin time 
  
 The prothrombin time is a measure of the extrinsic pathway of 
coagulation and quantifies the activity of coagulation factors VII, V, and X, 
along with their ability to produce fibrin from fibrinogen through the action of 
thrombin[77]. As some of the coagulation factors have short half lives-for 
example, factor VII has a half life of only two to five hours -the prothrombin 
time is a good marker of the synthetic capacity of the liver and hence reflects 
the severity of hepatic necrosis. It has been observed that the prothrombin time 
peaks on the third day after paracetamol overdose in those patients who are 
going to survive and on the fourth day or later in those who will not[78]. This 
presumably reflects either a greater degree of hepatic necrosis or a delay in 
hepatocyte regeneration in those patients who die. Prothrombin time is 
reproducible and nearly always available. Prothrombin time has emerged as a 
very discernible indicator of liver cell function especially acute liver cell 
function. 
 
   Other coagulation factors[77] 
 
Factor VII concentration has been shown to provide a good indication of 
prognosis in acute liver diseases. The use of serial factor VII concentrations has 
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also been shown to improve the predictive power of this test. Bernuau et al in 
Paris, using multivariate analysis, found that a reduced factor V concentration 
was the most sensitive prognostic indicator in patients with fulminant hepatitis 
B infection. However Assay of individual clotting factors is not a routine 
investigation in most laboratories and this limits the usage of these indicators in 
routine clinical practice[78]. 
 
     
 
 
    Aminotransferases 
 
 
 The serum aminotransferases (formerly called transaminases) are 
sensitive indicators of liver cell injury and are most helpful in recognizing acute 
hepatocellular diseases, such as hepatitis[79]. The activities of alanine 
aminotransferase (ALT), formerly serum glutamic-pyruvic transaminase 
(SGPT), and aspartate aminotransferase (AST), formerly serum glutamic-
oxaloacetic transaminase (SGOT), in serum are the most frequently measured 
indicators of liver disease. These enzymes catalyze the transfer of the α-amino 
groups of alanine and aspartic acid, respectively, to the α-keto group of 
ketoglutaric acid. This results in the formation of pyruvic acid and oxaloacetic 
acid. 
37 
 
 There is a poor correlation between the extent of liver cell necrosis and 
elevation of serum aminotransferases levels. Similarly, absolute elevation of 
aminotransferase levels is of little value in predicting the outcome of acute 
hepatocellular disorders. Rapid decreases in serum aminotransferase levels 
usually are a sign of recovery from disease. This may be a poor prognostic sign 
in fulminant hepatitis, in which decreasing serum values may reflect the 
massive destruction and loss of viable hepatocytes. AST has been validated as 
an independent prognostic marker in drug induced liver disease[80]. Other 
enzymes like lactate dehydrogenase, glutamate dehydrogenase, isocitrate 
dehydrogenase and sorbitrate dehydrogenase has been used as indictors of liver 
cell damage but none of them has been validated as prognostic indicators. 
 
     Bilirubin 
 A recognition of the potentially grave significance of yellow 
discoloration (jaundice) long preceded any knowledge of bilirubin and is 
mentioned in clay tablets of Mesopotamia (3000 BC) and the writings of 
Hippocrates (460–377 BC). In the practice of medicine over the centuries, the 
skin discoloration often evoked fear and loathing[81]. The concentration of 
bilirubin in plasma varies directly with the generation of bilirubin and inversely 
with the hepatic clearance of bilirubin. Bilirubin is incorporated in most of the 
scoring systems assessing the prognosis in liver diseases. Bilirubin has 
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separately been validated as an independent prognostic marker in drug induced 
liver diseases[80]. 
 
  Other prognostic markers in liver disease 
 Computerized tomagraphic liver volumetry has been validated as a 
prognostic indicator in acute liver disease[82]. The newer methods used in 
prognostication of liver diseases are ER6Q,Vimentin, actin alpha 1 skeletal 
muscle protein, hMFAP and tropomyosin[83]. Serum electrophoresis has been 
suggested as an indicator of prognosis in chronic liver disease.When an 
electrophoretic analysis of the serum proteins was included, marked decreases 
in the concentrations of albumin and the alpha-globulins alpha-1-antitrypsin and 
haptoglobin were observed in terminal liver cirrhosis, indicating impaired liver 
function[84].   In patients with alcoholic cirrhosis, plasma calprotectin has been 
suggested as a new prognostic marker of survival, which seems independent of 
the severity of liver disease[85]. Furthermore, high plasma calprotectin levels 
may characterize a group of patients with cirrhosis with recurring bacterial 
infections. 
Hyaluronic acid is a strong predictor of liver-related events in HIV/viral 
hepatitis-co-infected patients. Patients developing liver-related events during 
follow-up had substantially larger increases in HA compared to patients without 
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such events. Plasma Hyaluronic acid may be useful to monitor progression of 
liver disease in this population[86]. 
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   Thyroid function tests as prognostic indicators in liver disease 
 
 The abnormalities of serum concentrations of thyroid hormones are 
commonly found in liver diseases. The degree of abnormalities may be noted 
according to the type of disease or its severity. The estimation of free thyroid 
hormones is important in liver diseases because changes of the binding protein 
in blood. 
 According to Takahashi et al in chronic liver diseases, serum FT3 is 
decreased according to the degree of liver dysfunction in conditions such as 
CPH, CAH and LC, and seemed to reflect the severity of the liver damage[87]. 
Serum FT3 may reflect directly the disturbance of the conversion from T4 to T3 
in liver. It is also decreased in AH as in LC. Therefore serum FT3 may become 
an index of liver damage because serum FT3 showed favourable correlation 
with each of ICGR15, 
PT and albumin which were considered to reflect the reserved hepatic capacity. 
As to the significance of free thyroid hormones as an index of the severity of 
liver damage, serum FT3 decreased according to the degree of liver dysfunction 
in both chronic liver diseases and AH. In consequences it is considered that 
serum FT3 may become a sensitive index of liver dysfunction; serum FT4 
decreased in only LC[87]. It is considered that decrease of serum FT4 was noted 
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under the critical condition in liver diseases as in other diseases. Therefore 
serum FT4 is assumed to be a useful index for prognosis, and has a different 
significance 
from serum FT3. 
 Yamanaka et al reported that T3/T4 value decreased only decompensated 
liver cirrhosis, but no significant changes were noted in other liver diseases[88]. 
Yamaba et al reported that T3/T4 value decreased most in acute hepatitis, and 
slightly decreased in chronic persistent hepatitis and chronic active hepatitis, 
while no significant difference was noted in liver cirrhosis compared with 
controls[89]. 
 
 Ertugˇ rul Kayacetina, Gurcan Kısakolb, Ahmet Kayab found no 
significant difference in functional thyroid parameters between patients 
surviving and not surviving hepatic encephalopathy (p <0.375)[90]. They 
concluded that patients with decompensated liver disease complicated by 
hepatic encephalopathy subsequent to non-alcoholic cirrhosis were found to 
have exceedingly low serum FT3 and T4 levels. Depressed serum FT3 and T4 
levels, together with a prolonged prothrombin-time, therefore appear to be 
characteristic of a subgroup of decompensated cirrhotic patients prone to 
develop hepatic encephalopathy. 
 
 Hepner and Walfish reported a significant inverse correlation between 
42 
 
serum T3 concentrations and the severity of liver dysfunction[91,92]. A 
progressive decrease in T3 levels in chronic liver diseases was described as an 
indicator 
of poor prognosis. Authors ascribed this finding to diminished conversion of T4 
to T3 and impaired metabolism of thyroxine-binding proteins. Borzio et al. 
compared cirrhotics with normal subjects and chronic hepatitis patients. They 
suggested that T3 serum levels inversely paralleled severity of liver 
dysfunction. Thyroid function tests have also been performed in acute hepatitis. 
T4 has been found to be elevated in patients with acute viral hepatitis due to 
elevation of TBG 
(Possibly secondary to release from injured hepatocytes). 
 
 In a large group of alcoholic patients Israel et al reported a significant 
inverse correlation between serum T3 concentrations and the severity of liver 
dysfunction as well as a progressive T3 increase in those subjects eventually 
displaying a favourable outcome, suggesting that T3 concentrations in patients 
with advanced liver disease may be considered as a helpful prognostic 
indicator[93]. Only little data have been previously reported on direct 
measurement of free thyroid hormones in liver patients. Green et al found 
normal FT3 and FIT4 in a small group of cirrhotic patients while low FT4 and 
normal FT3 concentrations were present in alcoholic fatty liver[94]. Many studies 
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performed with equilibrium dialysis, however, showed decreased FT3 and 
normal or frequently increased FT4 concentrations. 
 
 S. OZSOY et al found out that chronic alcohol consumption may cause 
long-term thyroid dysfunction[95]. This may be manifested as a subclinical 
hypothyroidism in clinical settings and may be related to the severity and 
duration of alcoholism, family history, and aggression tendency of the patient. 
Although decreased thyroid hormone levels seem to be a result of persistent 
effect of chronic alcohol use on thyroid gland, it cannot be disregarded that it 
may also be a trait marker of proneness to alcoholism. 
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          Conclusion 
  
 The liver is closely involved in the metabolism and homeostasis of 
thyroid hormones. Liver synthesizes most of the thyroid binding proteins and is 
also involved in the peripheral conversion and inactivation of thyroid hormones. 
Clinically chronic liver disease may mimic hypothyroidism and thyroid 
dysfunction may exacerbate liver disease. Though most of the liver disease 
patients remain euthyroid, subtle abnormalities in thyroid function tests are 
common. The abnormalities found in a particular liver disease patient depend on 
the type and duration of illness. The thyroid abnormalities found in acute liver 
disease differs from that in chronic liver disease and reflects mostly the 
underlying inflammatory status. The thyroid abnormalities in chronic liver 
disease patients have been suggested to be an adaptive response to the disease 
state. It has also being suggested that induced hypothyroidism may be 
therapeutic in cirrhotic patients. Apart from this thyroid and liver dysfunction 
can coexist as part of consequences of drugs, radiation or other systemic disease 
process. 
 
 Accurate prediction of prognosis in liver disease is important in selecting 
the optimum treatment is especially important if liver transplantation is being 
planned. Several prognostic markers and scoring systems have been developed 
and validated in this regard. But the search for newer prognostic markers is still 
on. Several studies have suggested that thyroid function tests could powerful 
predictors of prognosis in liver disease. It has also being suggested that thyroid 
function tests can be used to differentiate between acute and chronic liver 
diseases. 
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   Materials and Methods 
 
Settings  
Institute of internal medicine,  
Madras Medical College and Government General Hospital  
Chennai - 600 003. 
 
Ethical approval 
 Obtained  
 
Study duration 
 
This study was conducted for a period of eighteen months from Jan 2008 to 
October 2009. 
 
 
Study Design  
 
A cross sectional study to determine the spectrum of thyroid 
abnormalities in acute and chronic liver disease  patients getting admitted to 
general medical wards during the study period.  
 
Inclusion criteria 
 
1] Patients admitted in medical wards in Government General Hospital with 
diagnosis of acute or chronic liver disease from January 2008 to October 2009 
were selected for the study. The first 50 patients admitted during the period with 
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diagnosis of chronic liver disease were studied under the chronic liver disease 
category. Similarly the first 10 patients with the diagnosis of acute liver disease 
were studied. 
         
2] Age greater than 12 years. 
 
 
Exclusion criteria 
1) Age less than 12 years 
2) Patients refusing to undergo the study 
 
Methods  
 
 A detailed clinical history was elicited from patients selected for the 
study. A comprehensive physical examination was carried out on them, 
followed by a thorough review of their hospital records. Data was collected 
regarding the duration of symptoms, clinical features of liver disease and 
features of thyroid disease. Patients were divided into acute or chronic liver 
disease based on history, physical examination, and imaging. Any patient with 
duration of illness more than 2 months was considered to have chronic liver 
disease. On imaging coarse echoes and features suggestive of cirrhosis was 
taken as markers of chronic liver disease. Ascites was graded into three 
categories; 0- no ascites, 1- easily controlled ascites, 2- difficult to control 
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ascites. Hepatic encephalopathy was graded into 3 categories; 0-none, 1-
minimal and 2-advanced. 
Complete thyroid profile (thyroid stimulating hormone [TSH], free 
thyroxine [FT4], total thyroxine [TT4], free triiodothyronine [FT3] and total 
triiodothyronine [T T3]) of patients selected for the study was carried out using 
chemilumiscent immunological method. Patients underwent complete liver 
function tests. This included total and direct bilirubin, enzymes (aspartate 
aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase 
[AP]), serum total protein and albumin and prothrombin time. Prothrombin time 
was estimated using method. All patients underwent an abdominal 
ultrasonogram to confirm the diagnosis and to look for ascites splenomegaly 
and features of portal hypertension. 
Child-Pugh score was calculated for patients with chronic liver disease as a 
measure of the severity of liver disease. 
 
 Thirty age and sex matched healthy controls were selected from among 
the attendees of the patients. They were given a complete physical examination 
liver function test evaluation to exclude liver disease. A complete thyroid 
profile (TSH, FT4, TT4, FT3, and TT3) was carried out on them. 
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   Statistical analysis 
 
 
 
Data analysis was done with use of SPSS, version 10. Descriptive 
statistics were used to calculate the frequency, mean, median, and standard 
deviation. For all normally distributed variables, Student’s t test and ANOVA 
test were used to determine the significant mean difference in various groups. 
The correlation between the various thyroid function variables and liver 
function variables was assessed by Pierson’s method.  The significance of the 
difference between the various coefficients of correlations was evaluated using  
z transformation test. 
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Observations and Results 
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   Observations and Results 
 
 The analysis of the data from 50 patients with chronic liver disease, 10 
patients with acute liver disease and 30 controls is given below. 
 
   Baseline characteristics 
 
 The baseline characteristics of each group of patients and controls are 
given below. The chronic liver disease group was composed 41 males and 9 
females. The average age was 49 years. The mean duration of symptoms was 
16.44 months. Twenty five patients had evidence of upper gastrointestinal 
bleed. Thirteen patients had evidence of hepatic encephalopathy with 4 of them 
having severe encephalopathy. Twenty nine patients had clinical evidence of 
ascites of which 6 were classified as difficult to control. Thirty four of these 
patients had serologic evidence of ascites. Of these patients 42 were clinically 
icteric while 30 had evidence of edema. 
 Of the chronic liver disease patients only one patient had clinical 
evidence of hypothyroidism and her thyroid profile showed gross 
hypothyroidism with TSH being 28.4. Two other patients had TSH between 5.5 
and 10 with no clinical evidence of hypothyroidism. No patient was found to 
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have either laboratory or clinical evidence of hyperthyroidism. Other baseline 
characteristics are given in the chart below. 
Characteristic                      Value   Standard deviation 
Total patients enrolled 50  
Male  41 (82%)  
Female  9 (18%)  
Mean age  49 yrs   12.8 years 
Mean Duration of 
symptoms 
16.44 months 19.8 months 
Number with UG bleed 25 (50%)  
Number with 
encephalopathy 
13 (26%)  
Number with severe 
encephalopathy 
4 (8%)  
Number with ascites 29 (58%)  
Number with difficult to 
control ascites 
6(12%)  
Number with jaundice 42 (84%)  
Number with edema 30 (60%)  
Patients with goiter 1 (2%)  
Patients with gall stones 3(6%)  
Patients with clinical 
hypothyroidism 
1 (2%)  
TSH 2.3788  mIU/L 4.01 
TT4  6.5778  micro g/dL 1.77 
FT4 1.1632  ng/dL 0.362 
TT3  102.64  ng/dL 38.0 
FT3 1.8728  pg/mL 0.650 
Total bilirubin 7.7390 mg/dl 5.69 
Direct bilirubin 4.3340 mg/dl 3.44 
AST 125.24  U/L 89.4 
ALT 128.94  U/L 117 
Alkaline phosphatase 198.26  U/L 59.8 
Albumin 3.2980 gm/dl 0.446 
Prothrombin time 24.086 seconds 6.34 
Child-Pugh score 10.120 2.19 
Liver size 11.170 cm 1.86 
Spleen size 10.900 cm 2.68 cm 
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Baseline characteristics in acute liver disease patients 
 
  The acute liver disease group consisted of 7 males and 3 females. The 
mean age of the group was 33.3 years. The mean duration of symptoms was 
0.360 months. All ten patients were jaundiced; none of the patients had upper 
gastrointestinal bleed, goiter or gall stones. One patient each had hepatic 
encephalopathy and ascites. 
 
 None of the patients had clinical or laboratory evidence of 
hypothyroidism or hyperthyroidism. The mean TSH was 1.7330 with a standard 
deviation of 1.04. The mean free T3 was 2.3090 with a standard deviation of 
0.644. The other baseline characteristics of the group are given below.
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Characteristic                      Value   Standard deviation 
Total patients enrolled 10  
Male  7 (70%)  
Female  3 (30%)  
Mean age  33.300 years 11.2  years 
Mean Duration of 
symptoms 
0.36600 months  0.119 months 
Number with UG bleed 0  
Number with 
encephalopathy 
1 (10%)  
Number with severe 
encephalopathy 
0  
Number with ascites 1 (10%)  
Number with difficult to 
control ascites 
1 (10%)  
Number with jaundice 10(100%)  
Number with edema 0  
Patients with goiter 0  
Patients with gall stones 0  
Patients with clinical 
hypothyroidism 
0  
TSH 1.7330  mIU/L 1.04 
TT4  9.9930  micro g/dL 2.52 
FT4 1.2720  ng/dL 0.279 
TT3  108.70  ng/dL 35.8 
FT3 2.3090  pg/mL 0.644 
Total bilrubin 7.7500 mg/dl 4.46 
Direct bilrubin 4.3400 mg/dl 3.33 
AST 317.30  U/L 219. 
ALT 325.60  U/L 230 
Alkaline phosphatase 208.00  U/L 38.1 
Albumin 3.6900 gm/dl 0.224 
Prothrombin time 16.260 seconds 2.12 
Liver size 12.180 cm 1.38 
Spleen size 7.6000 cm 0.745 
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   Baseline characteristics of control group 
 
 The control group consisted of 30 patients of which 20 were males. The 
mean age of the patients was 43.200 years. None of the patients had clinical or 
laboratory evidence of thyroid dysfunction. The liver function was normal both 
clinically and by laboratory evidence. 
 
 
 
 
Characteristic                      Value   Standard deviation 
Total patients enrolled 30  
Male  20 (66.67%)  
Female  10 (33.33%)  
Mean age  43.200 years 13.8 years 
Patients with clinical 
hypothyroidism 
0  
TSH  2.7440  mIU/L 1.56 
   
TT4   7.4693  micro g/dL 1.46 
FT4 1.2630  ng/dL 0.292 
TT3   124.17  ng/dL 29.0 
FT3 2.8850  pg/mL  0.582 
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  Distribution of patients in various groups 
 
 
 
Figure 2 distribution of patients 
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Sex distribution in various groups 
 
Chronic liver disease. Total number 50. Male-41, female-9. 
 
 
Figure 3 sex distribution CLD 
 
Acute liver disease  
Total number 10, female-3. Male-7 
 
 
Figure 4 ALD sex distribution 
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   Sex distribution in controls 
 
 
 
 
 
Figure 5 control sex distribution 
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  Comparison of thyroid function variables  
 
 The comparison between the thyroid function tests of the three groups 
was carried out using ANOVA test.  Among the thyroid function tests TSH and 
FT4 failed to show any statistically significant difference among them (p value 
of 0.67 and 0.35 respectively). The most statistically significant difference was 
in the comparison of TT4 and FT3 (p value -0.0001). The p value for the 
comparison of TT3 among the three groups was 0.033. 
 
 
 
Thyroid 
variable 
TSH1
Mean-std 
dev 
TT42
Mean-std 
dev 
TT33
Mean-std 
dev 
FT44
Mean-std 
dev 
FT35
Mean-std 
dev 
CLD 2.3788- 
4.01 
 6.5778 - 
 1.77 
102.64- 
38.0 
1.1632- 
0.362 
1.8728- 
0.650 
ALD 1.7330 - 
1.04 
9.9930- 
 2.52 
108.70 -
35.8 
1.2720 - 
 0.279 
2.3090- 
0.644 
CONTROL 2.7440- 
1.56 
7.4693 - 
1.46 
124.17- 
29.0 
1.2630- 
0.292 
2.8850 - 
0.582 
 
 
                                              
1 P value- 0.67 
2 P value- .0001
3 P value- 0.033
4 P value- 0.35
5 P value- .0001
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  The comparison of liver function abnormalities  
 
 There was no significant difference between the acute and the chronic 
disease groups in case of total or direct bilirubin. Among the enzymes both AST 
and ALT differed significantly between the two groups. Serum alkaline 
phosphatase did not vary significantly between the two groups. Markers of 
hepatic synthetic function like albumin and prothrmbin time varied significantly 
between the two groups. Among the sonologic parameters liver size did not 
show any significant difference while the difference in spleen size was 
significant. The comparison between the various liver function values and the 
level of significance is given in the table below. 
 
 
Liver function 
variable 
CLD 
Mean-std dev 
ALD 
Mean-std dev 
P value 
Mean-std dev 
Total bilirubin  7.74 -5.69 7.78-4.46 0.98 
direct bilirubin  4.33-3.44 4.34- 3.33 1.00 
AST 125- 89.4 317-  219 .0001 
ALT 129- 117 326- 230 0.0002 
ALK PO4 198- 59.8 208- 38.1 0.62 
Albumin 3.30-  0.446 3.69- 0.224 .0001 
Prothrombin time 24.1- 6.34 16.3- 2.12 0.0003 
Liver size 11.2-1.86 12.2-1.38  0.11 
Spleen size 10.9- 2.68 7.60 - 0.745 0.0003 
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Correlation between the thyroid function and liver function 
 
Correlation between the thyroid function and liver function in CLD 
 
 The correlation between various thyroid function variables and liver 
function variables was calculated using Pierson’s coefficient of correlation 
method. The results are shown in the table below. There was no significant 
relation between the thyroid function and the level of liver enzymes (AST, 
ALT). Among the thyroid function tests FT3 showed the highest level of 
correlation with the liver function indices. TSH did not show any correlation 
with the liver function indices except total bilirubin. The correlation was 
significant with a p value of less than 0.05. All other thyroid function indices 
showed relationships with the liver indices (excluding the enzyme levels) that 
were significant with a p value less than 0.01. Serum albumin showed a 
significant positive correlation with   TT4, TT3, FT4 and FT3. Both 
prothrombin time and child-Pugh score showed a significant negative 
correlation with TT4, TT3, FT4 and FT3. The best correlation was between FT3 
and Child-Pugh score. 
 T B D B AST ALT ALB P T CPS 
TSH +0.304a +0.189 -0.072 -0.014 -0.178 +0.366b +0.222 
TT4 -0.405b -0.515b +0.261 +0.231 +0.427b -0.595b -0.651b 
FT4 -0.446b -0.432b +0.137 +0.132 +0.412b -0.564b -0.481b
TT3 -0.580b -0.575b +0.110 +0.050 +0.486b -0.626b -0.535b
FT3 -0.599b -0.582b +0.117 +0.028 +0.505b -0.726b -0.682b
                                              
a  correlation significant at 0.05 level  ( 2 tailed) 
 
b correlation significant at 0.01 level  ( 2 tailed) 
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  Graphical representation of the data 
 
Plot between FT3 and liver variables 
Free T3 - albumin 
 
 
Figure 6 free T3- albumin 
 
 
 
The coefficient of correlation – 0.505 
Correlation significant at 0.01 level. 
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 Plot between free T3 and prothrombin time 
 
 
 
 
 
Figure 7 free T3- prothrombin time 
 
 
 
The coefficient of correlation between free T3 and prothrombin time – -0.626 
Correlation significant at 0.01 level. 
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  Plot between free T3 and total bilirubin 
 
 
 
 
 
Figure 8  FT3 - total bilirubin 
 
 
The coefficient of correlation between free T3 and prothrombin time – -0.599 
Correlation significant at 0.01 level. 
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 Plot between free T3 and Child‐Pugh score 
 
 
 
 
Figure 9 FT3-Child-Pugh score 
 
 
The coefficient of correlation between free T3 and Child-Pugh score – -0.599 
Correlation significant at 0.01 level. 
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Correlation between the thyroid function and liver function in ALD 
 
 The correlation between various thyroid function variables and liver 
function variables was calculated using Pierson’s coefficient of correlation 
method. The results are shown in the table below.  
 There was no significant relation between the thyroid function values and 
the level of liver enzymes (AST, ALT). Among the thyroid function tests FT3 
showed significant negative correlation with prothrombin time while the p value 
for the correlation with other variables did not reach level of significance, 
probably due to the small number of patients. TSH did not show significant 
correlation with any of the liver function indices. Total t4 showed a significant 
positive correlation with total bilirubin and a significant negative correlation 
with serum albumin levels. Total T3 showed significant negative correlation 
with AST levels. The level of correlation between other thyroid variables and 
various liver function values did not reach significant level. 
 
 
                                              
 T B D B AST ALT ALB P T 
TSH -0.192 -0.274 +0.444 +0.357 +0.028 -0.180 
TT4 +0.857a +0.890 +0.466 +0.433 -0.862a +0.355 
FT4 +0.408 +0.438 -0.214 -0.108 -0.222 +0.171 
TT3 -0.587 -0.588 -0.644b -0.559 +0.444 -0.485 
FT3 -0.605 -0.611 -0.129 -0.057 +0.282 -0.730b
a  correlation significant at the 0.01 level ( 2 tailed) 
b correlation significant at the 0.05  level ( 2 tailed) 
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 Plot between total T4 and serum albumin levels 
 
 
 
 
 
 
Figure 10 total t4- serum albumin 
 
 
 
 
 
The coefficient of correlation between total T4 and serum albumin – 0.857 
Correlation significant at 0.01 level 
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 Plot between total T4 and total bilirubin levels 
 
 
 
 
Figure 11 total T4- total bilirubin 
 
The coefficient of correlation between total T4 and total bilirubin - +0.862 
Correlation significant at 0.01 level 
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 Plot between free T3 and prothrombin 
 
 
 
 
 
Figure 12 FT3- prothrombin time 
 
 
The coefficient of correlation between total T4 and total bilirubin - -0.730 
Correlation significant at 0.05 level. 
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  Plot between total T3 and AST 
 
 
 
 
 
Figure 13 total T3- AST 
 
 
The coefficient of correlation between total T3 and AST - -0.644 
Correlation significant at 0.05 level. 
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Analysis of the difference between the various correlations 
 
 The significance of the difference between the various values of 
correlation was assessed by Z- transformation test. There was no significant 
difference between the statistically significant correlation values. The data 
obtained in the analysis is given in the following table. 
 
 CLD 
group                
  type n r z 1/n-3 se(z1-z2)   
P-
value 
PT free_3 50 -0.726 
-
0.92022 0.021277       
  tot_t3 50 -0.626 
-
0.73481 0.021277       
        
-
0.18541 0.042553 0.206284 
-
0.89879 0.369 
CP free_3 50 -0.682 
-
0.83284 0.021277       
  tot_t3 50 -0.535 
-
0.59712 0.021277       
        
-
0.23572 0.042553 0.206284 
-
1.14269 0.253 
 ALD 
Group                
PT free_3 10 -0.73 
-
0.92873 0.142857       
  tot_t3 10 -0.485 -0.5295 0.142857       
        
-
0.39923 0.285714 0.534522 
-
0.74688 0.455 
 
     Discussion 
 
 Baseline characteristics of the data show that the majority of the liver 
disease population is constituted by males, both in acute and chronic liver 
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disease groups. Among these two groups, males constituted a higher proportion 
(82%) in the chronic liver disease group. This probably reflects the high 
prevalence of alcohol abuse among males. Another reason could be greater 
exposure of the males to infectious agents due to their outdoor lifestyle. 
   
 Among the chronic liver disease patients only one patient had gross 
hypothyroidism, she also had clinical evidence of thyroid disease. Two other 
patients showed elevated TSH between 5 and 10 without clinical evidence of 
hypothyroidism. There were no other gross abnormalities in any of the other 
patients in chronic liver disease group or acute liver disease group. So it can be 
inferred that all chronic liver disease patients should be carefully examined for 
features of hypothyroidism and if it is present laboratory confirmation is 
warranted. The usefulness of routine screening for thyroid abnormalities in 
chronic liver disease patients is doubtful as there is uncertainty regarding the 
benefit of treating patients with subtle thyroid abnormalities. This concern is 
especially valid since many investigators have suggested that hypothyroidism 
may be an adaptive change liver cirrhosis patient. 
 
 On analysing the thyroid function variables, TSH did not vary 
significantly between the three groups (p value-0.67). Total T4 was significantly 
lower in the chronic liver disease group compared to controls and acute liver 
disease (p value .0001). The total T4 level was significantly elevated in acute 
liver disease group (p value .0001). This reiterates the fact that total T4 is an 
acute phase reactant and is elevated in any conditions causing systemic 
inflammation. Total T4 may emerge as a useful marker to differentiate between 
acute and chronic liver disease patents as the values go in different directions 
from normal in these two groups. A potential caveat to this approach would be 
chronic liver disease patients with significant inflammation. 
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 Total T3 was significantly lower in both the disease groups compared to 
controls (p value .033) probably due to impaired peripheral conversion in liver 
disease groups. Free T4 did not vary significantly between the three groups. 
This was surprising given that earlier studies have demonstrated significant 
difference between these groups. It has previously been proposed that free T4 
could be used as an indicator to differentiate acute and chronic liver disease 
patients as it is decreased only in chronic liver disease patients. 
   
 Free T3 differed significantly between all the three groups with chronic 
liver disease group having the lowest value. The difference between the acute 
liver disease group and controls was also significant (p value .0001). So free T3 
may be used as a sensitive indicator to differentiate acute and chronic liver 
disease patients. For this separate normal limit of free T3 has to be established 
in both acute and chronic liver disease groups by large population studies.  
  
 The chronic liver disease group was considerably older than the acute 
liver disease group. The acute liver disease group was less sick with better 
prothrombin time (p value-<0.0001). The enzyme levels, both AST and ALT 
differed significantly between the two groups (p value-<0.0001).among the 
ultrasound parameters spleen size varied significantly (p value-<0.0001) but 
there was no significant difference in liver size (p value-0.11). There was no 
significant difference between the total or direct bilirubin levels between the 
two groups (p value-0.98). These results were along the expected levels. 
 
 On assessing the correlation between thyroid and liver function variables 
in the chronic liver disease group, TSH showed significant correlation only with 
total bilirubin (p value of < 0.05). In the acute liver disease group TSH did not 
show any significant correlation with any of the liver function variables. 
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  In chronic liver disease patients total T4 showed significant negative 
correlation with total bilirubin, direct bilirubin, prothrombin time and Child-
Pugh score (p value of < 0.01). There was significant positive correlation 
between serum albumin levels and total T4 (p value of < 0.01). This was in 
contrast to the situation in acute liver disease group where there was significant 
positive correlation between total T4 levels and total bilirubin and direct 
bilirubin and significant negative correlation with serum albumin levels. There 
was no significant correlation between total T4 and other liver variables despite 
high coefficient of correlation value. This was due to the small number of 
subjects in the acute liver disease study group (10). It can be concluded that in 
chronic liver disease total T4 decreases as the severity of the disease worsens 
but in acute liver diseases total T4 increases as the disease severity worsens. 
This may be due to the fact that in acute liver disease group it acts as a marker 
of inflammation while in chronic liver disease group it is decreased probably 
due to direct suppression of the thyroid function in chronic liver disease group 
or abnormalities in pituitary thyroid axis. 
 
 Free T4 follows the same pattern of relationship with liver function 
variables as total T4 in chronic liver disease. It showed significant negative 
correlation with total bilirubin, direct bilirubin, prothrombin time and Child-
Pugh score (p value of < 0.01). There was significant positive correlation 
between serum albumin levels and total T4 (p value of < 0.01). But when it 
came to acute liver disease it failed to show any statistically significant 
relationship. Moreover the relationship it showed was in inverse direction to the 
relationship with total T4 in case of enzymes. This again points to the fact that 
the elevation of total T4 in acute liver diseases is due to elevated thyroid 
binding globulin release from liver. 
 
75 
 
 Total T3 showed significant negative correlation with total bilirubin, 
direct bilirubin, prothrombin time and Child-Pugh score (p value of < 0.01). 
There was significant positive correlation between serum albumin levels and 
total T4 (p value of < 0.01). When it came to acute liver diseases it showed 
significant relationship only with AST which was negative (coefficient of 
correlation -0.644 with p value 0.05). Though coefficients of correlations with 
other liver variables were numerically robust, it did not reach levels of statistical 
significance due to the small number of patients. 
 
  Free T3 showed the highest level of correlation with liver variables 
whenever the relationship was significant. Free T3 showed significant negative 
correlation with total bilirubin, direct bilirubin, prothrombin time and Child-
Pugh score (p value of < 0.01). There was significant positive correlation 
between serum albumin levels and total T4 (p value of < 0.01). Among the 
different variables the highest correlation was between prothrombin time (-
0.726) and then Child-Pugh score (-0.682). In acute liver disease patients free 
T3 showed significant negative correlation with prothrombin time (-0.730). This 
shows that free T3 could be a useful marker of severity and prognosis in chronic 
liver disease patients as it has consistent and significant relationship with 
prothrombin time and Child-Pugh score. Free T3 maintains this strong 
relationship with prothrombin time in acute liver diseases. Since prothrombin 
time is widely regarded as one of the best prognostic indicator in acute liver 
diseases free T3 can be used as another marker of severity and prognosis. 
 
 Among the thyroid variables free T3 showed the highest correlation with 
the liver function variables. But this did not turn out to be significant 
statistically (p value 0.369). Even then by virtue of the higher coefficients of 
correlations it can be said that free T3 deserves maximum attention as a marker 
of liver disease severity and prognosis. In acute liver disease patients total T4 
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showed the highest and most significant correlation. So total T4 may be used as 
a marker of acute diseases in which it increases in contrast to chronic diseases in 
which it deceases. Regarding prognosis and severity free T3 showed significant 
correlation with prothrombin time, total T3 with AST and total T4 with 
bilirubin. The difference between free T3 and total T3 in their relationship with 
liver variables were not statistically significant (0.455). So it will be hard to 
recommend one value among these as a better index, but free T3 probably 
deserves more attention because of its relationship with prothrombin time. All 
these variables require validation in prospective studies before they can be 
considered be useful markers of prognosis. Further more their relationship liver 
function has to be established in each of the etiologically different liver 
diseases. 
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   Limitations of the study     
 
 There were many limitations to the study. The most important among 
them is that it was a cross sectional study without follow up of the patients. So 
the conclusions made regarding the prognosis of the patients are at best 
inadequate. Another major limitation of the study was the limited number of 
patients in the acute liver disease group. This was due partly to the pattern of 
hospital admission and to financial constrains. Assessment of reverse T3, 
reverse T4 and thyroid binding globulin (TBG) was not carried out as part of 
this study. Assessment of TBG levels would have made interpretation of T4 
levels more meaningful. 
 
 Assessment of liver disease was limited by lack of histological diagnosis. 
Histological diagnosis would have permitted further refinement in interpretation 
of the results. Another major drawback was the lack of etiological classification 
of the liver disease patients. Most of these shortcomings were due to financial 
constrains. 
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    Conclusions 
 
1) Males constitute the majority of liver disease patients in govt general 
hospital and this is more prominent in the chronic liver disease group. The 
chronic liver disease patients are sicker and have more complications than 
acute liver disease patients. 
 
2) Gross thyroid abnormalities are uncommon in liver disease patients if 
clinical features of thyroid dysfunction are absent. In every patient with 
liver disease signs of thyroid dysfunction should be looked for. Patients 
with features of thyroid dysfunction should promptly undergo laboratory 
evaluation. There is not enough evidence to suggest routine screening for 
thyroid dysfunction in liver disease patients in the absence of symptoms. 
 
 
3) Different thyroid function parameters differ significantly between chronic 
liver disease patients, acute liver disease patients and controls. This can be 
utilized in differentiating acute liver disease patients from chronic patients. 
For this total T4 seems to be the most promising followed by free T3 and 
total T3. 
 
4) Thyroid indices may be useful in assessing the prognosis of patients with 
liver disease since they show significant correlation with established 
markers of liver disease prognosis. In this regard free T3 seems to be the 
most promising in chronic liver disease patients. In acute liver disease 
there is nothing much to choose between total T4 and free T3. 
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5) Further prospective studies are required for validating and assessing the 
role of thyroid function tests as markers of prognosis in liver disease. 
Studies need to be carried out in each of the etiologically different liver 
diseases for better defining the role of thyroid hormones in each situation. 
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             Thyroid abnormalities in liver disease 
                                                   Performa 
Name 
Age 
Sex 
Date  
History 
• Thyroid illness-duration 
• Treatment taken 
• Duration of liver disease 
• Complications  
• UGI bleed 
• Hepatic encephalopathy 
• Ascites 
• Bleeding tendencies 
• Previous episodes of jaundice 
• Bowel habits 
• Features of hypothyroidism 
• Features of hyperthyroidism 
• Other clinical diagnosis 
Clinical examination 
• Icterus 
• Edema 
• Goiter 
• Bleeding manifestations 
• Ascites 
• Liver 
• Flapping tremor 
• reflexes 
Investigations 
• Total T4 
• Total T3 
• Free T4 
• Free T3 
• TSH 
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LFT 
• Total bilirubin 
• Direct bilirubin 
• AST 
• ALT 
• Alkaline phosphatase 
• Total protein 
• Albumin 
• PT -INR 
Ultrasound abdomen 
• Liver size 
• Texture 
• Nodules 
• Ascites 
• Spleen size 
• Portal hypertension 
• Gall stone 
 
Child-Pugh score 
Diagnosis  
 Liver disease 
 Thyroid status 
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serial 
no  
C LD age sex duration 
ug 
bleed 
encephlthy 
grade ascites 
feat 
hypo hyper icterus  edema 
tot 
t4 
free 
t4 
free 
t3 
tot 
t3 
1 60 m 2 1 2 2 0 0 1 1 3.07 0.84 1.26 72 
2 61 m 1 0 0 1 0 0 1 1 6.11 1.03 1.34 99 
3 45 m 12 1 1 1 0 0 1 1 6.87 1.34 1.36 122 
4 44 m 12  0 0 1 0 0 0 6.51 0.95 1.78 88 
5 46 m 24 1 1 2 0 0 1 1 4.4 0.97 1.55 72 
6 56 f 24 0 0 1 0 0 1 1 4.6 1.08 1.65 97 
7 46 m 1 0 2 0 0 0 1 0 6.75 1.43 1.79 124 
8 57 f 30 0 0 1 0 0 1 1 7.4 1.22 2.33 175 
9 25 m 1 0 0 0 0 0 1 0 11.8 1.26 2.34 123 
10 46 m 24 1 0 2 0 0 1 1 4.32 1.02 1.34 67 
11 64 m 18 0 0 0 0 0 1 0 6.88 1.67 1.38 98 
12 58 m 36 1 2 2 0 0 1 1 4.78 0.79 1.23 86 
13 34 m 24 0 0 0 0 0 1 0 6.78 1.54 2.67 145 
14 45 m 15 1 0 1 0 0 1 1 5.43 1.21 1.71 76 
15 54 m 48 1 1 1 1 0 1 1 2.33 0.32 0.24 23 
16 38 f 24 1 0 1 0 0 1 0 6.79 1.45 1.97 103 
17 68 m 36 0 0 1 0 0 1 1 4.78 1.02 1.47 57 
18 58 m 4 1 0 1 0 0 0 0 8.76 1.56 2.46 135 
19 42 m 6 0 0 0 0 0 1 0 6.78 0.94 3.12 104 
20 39 m 12 1 0 0 0 0 1 1 4.85 0.83 1.17 64 
21 63 f 9 1 0 1 0 0 1 0 6.92 0.94 1.25 38 
22 38 m 4 1 0 0 0 0 1 0 8.42 1.24 1.98 102 
23 56 m 6 1 1 1 0 0 1 1 5.71 0.87 1.43 59 
24 44 m 12 0 0 1 0 0 1 1 6.83 1.42 1.94 84 
25 35 m 8 0 0 1 0 0 1 1 7.43 0.97 1.96 134 
26 49 m 6 1 2 2 0 0 1 1 4.75 0.85 1.23 45 
27 72 f 24 0 0 1 0 0 1 1 6.74 1.23 1.84 85 
28 59 m 6 0 0 1 0 0 1 1 7.85 2.53 2.87 186 
29 57 m 14 1 0 1 0 0 1 1 5.42 0.94 1.36 83 
30 43 m 6 1 0 1 0 0 0 1 5.42 0.84 2.19 89 
31 76 m 3 0 0 1 0 0 1 1 8.74 1.56 1.56 169 
32 37 m 36 1 0 1 0 0 1 1 6.7 0.83 1.49 68 
32 68 f 48 1 0 0 0 0 0 0 8.91 1.34 2.46 146 
34 29 f         12 1 0 1 0 0 1 0 7.92 1.26 2.53 153 
35 58 m 12 0 0 1 0 0 1 1 4.78 0.86 1.75 78 
36 21 m 12 0 0 1 0 0 0 0 9.87 1.53 3.42 168 
37 46 m 3 1 1 2 0 0 1 1 4.32 0.77 1.32 57 
38 53 m 4 0 0 1 0 0 1 0 6.78 1.23 2.43 79 
39 39 m 3 0 1 1 0 0 1 1 5.78 1.02 1.12 123 
40 64 m 12 0 0 0 0 0 1 0 9.67 1.78 3.45 176 
41 40 m 6 1 0 0 0 0 0 0 7.41 1.04 2.13 124 
42 75 m 1 0 1 0 0 0 0 1 5.42 0.87 1.67 72 
43 34 m 3 0 0 0 0 0 1 0 6.34 1.45 2.13 123 
44 37 f 12 0 0 1 0 0 1 1 6.73 0.83 1.54 73 
45 46 m 6 1 1 1 0 0 1 1 5.87 0.83 1.57 98 
46 47 m 3 0 0 0 0 0 1 0 7.89 1.46 3.21 143 
47 54 m 6 1 0 0 0 0 0 0 8.34 1.54 2.47 124 
48 54 m 48 1 1 1 0 0 1 1 7.32 1.65 1.97 103 
49 38 m 12 1 0 1 0 0 1 0 8.23 0.99 1.93 124 
50 32 f 24 0 0 1 0 0 1 1 6.39 1.02 1.28 96 
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serial 
no  
CLD  t b d b ast alt 
alk 
po4 t p alb pt 
C P 
S 
liver 
size texture ascites spleen 
gall 
stones 
thy 
status 
1 3.5 2.3 67 45 93 7 4.5 23.1 13 9.3 1 1 11 0 1 
2 15.8 10.4 51 55 80 5.6 2.9 25.9 11 9.8 1 1 10.4 0 1 
3 3.8 2 71 86 123 6.4 3.5 26.9 10 11.1 1 1 8.6 0 1 
4 0.9 0.3 20 24 116 7.6 3.6 19.6 6 14.4 1 0 13.8 0 1 
5 7.8 4.5 98 120 198 7.5 3.2 26.7 11 10.4 1 1 12.4 0 1 
6 6.8 4.1 124 213 214 7.3 3.3 24.4 11 10.6 1 1 13.4 0 1 
7 7.9 4.3 342 543 198 6.9 3.6 17.4 9 13.2 1 0 7.8 0 1 
8 8.9 3.9 124 231 204 7.1 3.1 21.3 11 10.2 1 1 11.3 0 1 
9 3.5 2.3 445 564 235 7.3 3.9 17.4 7 13.4 1 0 6.7 0 1 
10 4.7 2.6 76 86 176 6.4 3.2 25.6 12 9.8 1 0 10.2 1 2 
11 12.7 7.6 112 142 189 6.7 3.1 29.8 10 11.2 1 0 8.7 0 1 
12 24.3 14.5 76 86 193 6.4 2.8 38.2 14 8.9 1 1 13.4 0 2 
13 3.4 1.6 56 76 87 7.3 4 14.3 7 10.3 1 0 7.5 0 1 
14 9.2 6.4 98 134 192 6.4 3 27.8 11 11.2 1 1 13.2 0 1 
15 14.5 5.7 94 104 187 6.8 3.1 34.5 12 12.3 1 1 12.5 1 3 
16 6.8 3.2 234 346 243 7 3.4 23.1 11 11.3 1 1 8.9 0 1 
17 12.8 7.8 94 98 178 6.4 2.8 34.5 11 10.2 1 1 12.4 1 1 
18 1.2 0.7 68 84 142 7.2 3.6 16.2 6 9.7 1 1 14.2 0 1 
19 2.7 1.4 58 73 188 6.8 3.6 23.1 8 14 1 0 8.5 0 1 
20 15.8 9.2 143 165 245 6.4 2.8 36.1 11 9.3 1 0 14.5 0 1 
21 21.2 8.9 92 143 241 6.7 2.9 32.1 11 11.4 1 1 13.4 0 1 
22 4.6 2.4 86 78 286 7.3 4.1 17.3 8 12.4 1 0 12.4 0 1 
23 14.5 9.3 94 128 194 6.8 2.6 28.5 13 11.3 1 1 17.8 0 1 
24 6.2 3.5 223 246 256 7.4 3.9 16.4 9 12.4 1 1 13.2 0 1 
25 3.55 1.3 245 78 423 7.3 4 23.4 10 12.7 1 1 10 0 1 
26 16.4 10.3 145 85 204 7.1 2.8 28.6 14 10.2 1 1 12.4 0 1 
27 7.8 4.5 254 346 178 7.2 3.2 19.8 10 12.2 1 1 12.4 0 1 
28 3.8 2.1 78 46 204 6.9 3.6 18.9 9 11.3 1 1 9.7 0 1 
29 9.3 7.4 168 67 196 7.2 2.9 32.6 11 9.7 1 1 8.7 0 1 
30 1.2 0.5 34 27 102 6.7 3.6 16.3 7 11.2 1 1 7 0 1 
31 4.6 1.9 87 56 213 6.9 3.6 24.2 10 14.5 1 1 8.5 0 1 
32 9.4 5.4 56 74 186 6.4 2.8 36.2 11 13.4 1 1 14.5 0 1 
32 1.8 0.8 54 46 201 6.8 3.6 17.5 6 9.7 1 0 15.7 0 1 
34 4.6 2.3 88 67 235 6.7 3.1 23.4 11 9.2 1 1 13.2 0 1 
35 10.1 6.7 178 132 321 6.4 2.9 26.7 11 11.5 1 1 9.8 0 1 
36 1.8 0.9 56 75 198 7.2 3.6 18.5 7 8.7 1 1 12.4 0 1 
37 24.3 14.5 134 67 234 6.4 2.7 35.4 14 7.8 1 1 10.1 0 1 
38 3.4 1.6 57 46 198 6.8 3.2 19.4 10 10.7 1 1 8.7 0 1 
39 7.5 3.7 87 76 234 6.4 2.8 24.3 13 8.8 1 1 9.4 0 1 
40 3.9 1.6 246 134 214 7.1 3.7 17.3 8 12 1 0 6.8 0 1 
41 2.5 1.1 57 54 253 6.9 3.6 18.4 7 14.5 1 0 13.2 0 1 
42 9.3 5.4 87 75 188 6.4 2.8 23.1 12 9.4 1 0 7.6 0 1 
43 3.8 2.1 93 75 276 6.9 3.6 18.5 8 14.3 1 0 7.9 0 1 
44 8.7 4.6 75 64 167 6.7 3 24.6 11 8.6 1 1 12.3 0 1 
45 6.4 4.5 192 84 248 6.5 2.7 26.7 13 8.3 1 1 8.9 0 1 
46 7.1 3.7 346 243 154 7.2 3.6 16.4 8 13.2 1 0 7.4 0 1 
47 3.1 1.6 49 65 134 7.1 3.8 17.4 8 11 1 0 7.2 0 1 
48 4.9 2.1 146 89 172 6.4 2.9 23.1 12 12.2 1 1 13.2 0 1 
49 4.9 1.4 58 64 154 6.9 3.5 21.1 11 9.9 1 1 8.6 0 1 
50 9.3 5.8 246 342 168 6.4 2.8 32.3 11 15.4 1 1 13.2 0 1 
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acute 
liver 
d. age sex duration 
ug 
bleed encephlthy ascites 
feat 
hypo hyper icterus  edema goitre 
tot 
t4 
free 
t4 
free 
t3 
tot 
t3 
1 24 m 0.5 0 0 0 0 0 1 0 0 10.34 1.04 1.47 78 
2 56 m 0.25 0 0 0 0 0 1 0 0 12.54 1.32 1.67 73 
3 35 f 0.25 0 0 0 0 0 1 0 0 8.75 0.94 2.46 83 
4 21 m 0.25 0 0 0 0 0 1 0 0 9.43 1.43 3.42 164 
5 36 f 0.5 0 0 0 0 0 1 0 0 7.35 1.46 2.96 156 
6 43 f 0.33 0 0 0 0 0 1 0 0 14.53 1.79 1.53 82 
7 34 m 0.25 0 0 0 0 0 1 0 0 8.74 0.93 2.57 137 
8 29 m 0.5 0 1 2 0 0 1 0 0 12.74 1.04 2.64 74 
9 18 m 0.33 0 0 0 0 0 1 0 0 6.78 1.32 1.94 106 
10 37 m 0.5 0 0 0 0 0 1 0 0 8.73 1.45 2.43 134 
 
 
acute  
liver 
d. t b 
d 
b ast alt 
alk 
po4 t p alb pt 
liver 
size texture ascites spleen 
gall 
stones 
thyroid 
status 
1 8.1 4.5 354 265 156 7.1 4 21 14.2 2 0 6.8 0 1  
2 16.4 10 175 169 193 7.2 3.9 16 12.4 2 0 7.8 0 1  
3 3.5 1.6 547 674 234 7 3.8 15 11.2 2 0 8.4 0 1  
4 4.6 2.6 167 231 178 7.3 4.2 14 12.5 2 0 7.4 0 1  
5 5.7 2.3 245 268 159 6.9 3.7 17 13.2 2 0 7.3 0 1  
6 14.6 10 476 563 246 6.8 2.9 19 12.4 2 0 7.4 0 1  
7 4.8 2.1 94 84 231 7.2 3.9 14 13.2 2 0 7.3 0 1  
8 9.6 5.3 763 682 254 7 2.9 15 9.2 2 0 9.3 0 1  
9 4.7 1.9 268 258 183 6.9 3.8 16 12.3 2 0 7.4 0 1  
10 5.8 2.6 84 62 246 6.4 3.8 15 11.2 2 0 6.9 0 1  
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controls age sex 
tot t4 
4.5-12.0 
free t4 
.70-1.80 
free t3 
1.7-4.2 
tot t3 60-
200 
tsh .35-
5.5 
1 36 m 10.64 1.74 3.54 163 3.45 
2 24 m 7.45 1.38 2.61 123 3.82 
3 56 m 8.76 1.52 2.91 142 2.63 
4 29 m 6.79 1.41 2.74 93 4.04 
5 67 f 8.41 0.92 3.17 108 2.87 
6 39 m 7.42 1.06 2.37 127 1.98 
7 42 f 5.43 0.89 1.93 88 5.02 
8 19 m 11.23 1.69 3.92 183 0.51 
9 61 m 9.36 1.42 3.16 142 0.71 
10 52 m 5.04 0.87 1.87 78 4.57 
11 36 f 7.09 1.25 2.67 108 2.36 
12 32 f 7.41 1.17 2.93 126 2.93 
13 47 m 8.42 1.23 3.45 131 3.07 
14 71 m 6.92 1.05 2.83 88 3.75 
15 57 f 5.91 1.26 2.46 92 3.54 
16 43 m 9.23 1.24 2.36 174 1.26 
17 22 m 7.54 1.17 3.42 137 1.86 
18 55 m 5.82 0.92 2.93 108 4.13 
19 29 f 6.82 0.89 2.16 112 1.47 
20 42 m 6.73 1.09 3.02 126 1.09 
21 39 m 7.83 1.26 2.79 154 1.04 
22 30 f 6.92 1.65 3.04 127 2.32 
23 47 m 5.63 0.92 1.82 72 7.32 
24 62 f 8.19 1.63 3.49 137 2.08 
25 60 f 7.34 0.87 2.15 99 4.32 
26 44 m 6.03 1.16 3.95 124 3.05 
27 34 m 7.89 1.62 3.85 156 0.73 
28 28 m 5.83 1.23 2.93 102 4.11 
29 42 m 8.37 1.49 3.02 132 1.18 
30 51 f 7.63 1.89 3.06 173 1.11 
 
 
